A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

NCT ID: NCT01242917

Last Updated: 2025-03-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 159 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-09-30
• Study Completion Date: 2011-07-31

Brief Summary

This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.

Detailed Description

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo film-coated tablets twice daily for 12 weeks + methotrexate

CCX354-C 100mg twice daily

Group Type: EXPERIMENTAL

CCX354-C

Intervention Type: DRUG

100mg film-coated tablets twice daily for 12 weeks + methotrexate

CCX354-C 200mg once daily

Group Type: EXPERIMENTAL

CCX-354-C

Intervention Type: DRUG

200mg film-coated tablets once daily for 12 weeks + Methotrexate

Interventions

CCX-354-C

200mg film-coated tablets once daily for 12 weeks + Methotrexate

Intervention Type: DRUG

Placebo

Placebo film-coated tablets twice daily for 12 weeks + methotrexate

Intervention Type: DRUG

CCX354-C

100mg film-coated tablets twice daily for 12 weeks + methotrexate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects, aged 18-75 years inclusive, with functional class I to III rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for at least 3 months prior to screening; wheel-chair bound subjects or those with irreversible disease will not be eligible;

2. Subjects must have active RA, defined by a minimum of 8 swollen joints and 8 tender/painful joints (based on 66/68 joint count), at screening

3. Serum C-reactive protein (CRP) above 5 mg/L at screening;

4. Must have been on methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly for ≥ 16 weeks and on a stable dose for ≥ 8 weeks prior to randomization;

5. If on hydroxychloroquine, must have been on a stable dose for ≥ 16 weeks prior to randomization;

6. If taking non-steroidal anti-inflammatory drugs (NSAIDs), must have been on stable doses for ≥ 2 weeks before randomization;

7. If taking oral corticosteroids, subjects may not take more than 10 mg/day of prednisone or equivalent, and must have been on a stable dose for ≥ 4 weeks before randomization;

8. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;

9. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen;

10. Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments;

11. Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after administration of study medication

Exclusion Criteria

1. Diagnosed with RA prior to 16 years of age;

2. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at screening;

3. History within one year prior to randomization of illicit drug use;

4. History of alcohol abuse at any time in the past;

5. Have received sulfasalazine, azathioprine, 6-mercaptopurine, mycophenolate mofetil, tetracycline, cyclosporine, gold, tacrolimus, sirolimus, or other disease modifying anti-rheumatic drug (DMARD) within 8 weeks of randomization;

6. Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomization;

7. Use of leflunomide within 6 months of randomization;

8. Use of etanercept or anakinra within 4 weeks of randomization;

9. Use of a B-cell depleting agent such as rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomization;

10. Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant, or verapamil;

11. Currently taking cytochrome P450 inducers including St. John's wort, rifampicin, rifabutin, rifapentin, dexamethasone, phenytoin, carbamazapine, phenobarbitol, or troglitazone;

12. Intra-articular, intravenous, or intramuscular corticosteroid injection within 4 weeks of randomization;

13. History or presence of any form of cancer within the 10 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;

14. Evidence of tuberculosis (TB) based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.

15. Presence of Felty's syndrome, psoriatic arthritis, gout, or other auto-immune diseases;

16. Major surgery (including joint surgery) within 12 weeks prior to randomization;

17. The subject had an infection requiring antibiotic treatment within 4 weeks of randomization;

18. Subject has any evidence of hepatic disease; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), alkaline phosphatase, or bilirubin > 1.5 x the upper limit of normal;

19. Subject has any evidence of renal impairment; serum creatinine > 1.5 x upper limit of normal or estimated Glomerular Filtration Rate (GFR) based on the Cockcroft-Gault equation < 30 mL/min;

20. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study

21. Participated in any clinical study of an investigational product including CCX354-C within 30 days or 5 times the half life of the agent, whichever is longer, prior to randomization

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Brussels, , Belgium

Kortrijik, , Belgium

Liège, , Belgium

Brno, , Czechia

Bruntál, , Czechia

Hlučín, , Czechia

Ostrava-Trebovice, , Czechia

Prague, , Czechia

Uherské Hradiště, , Czechia

Zlín, , Czechia

Berlin, , Germany

Frankfurt, , Germany

Hanover, , Germany

Herne, , Germany

Leipzig, , Germany

Mainz, , Germany

Würzburg, , Germany

Balatonfüred, , Hungary

Békéscsaba, , Hungary

Budapest, , Hungary

Székesfehérvár, , Hungary

Veszprém, , Hungary

Amsterdam, , Netherlands

Chełm Śląski, , Poland

Elblag, , Poland

Grodzisk Mazowiecki, , Poland

Krakow, , Poland

Lublin, , Poland

Poznan, , Poland

Warsaw, , Poland

Żyrardów, , Poland

Bacau, , Romania

Baia Mare, , Romania

Brăila, , Romania

Bucharest, , Romania

Galati, , Romania

Saint Gheorghe, Covasna, , Romania

Târgovişte, , Romania

Donetsk, , Ukraine

Kharkiv, , Ukraine

Kiev, , Ukraine

Countries

Belgium; Czechia; Germany; Hungary; Netherlands; Poland; Romania; Ukraine

Other Identifiers

2010-019964-36

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CL004_354

Identifier Type: -

Identifier Source: org_study_id